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Severe infections represent the main cause of neonatal mortality accounting for more than one million neonatal
deaths worldwide every year. Antibiotics are the most commonly prescribed medications in neonatal intensive care
units (NICUs) and in industrialized countries about 1% of neonates are exposed to antibiotic therapy. Sepsis has
often nonspecific signs and symptoms and empiric antimicrobial therapy is promptly initiated in high risk of sepsis
or symptomatic infants. However continued use of empiric broad-spectrum antibiotic treatment in the setting of
negative cultures especially in preterm infants may not be harmless.
The benefits of antibiotic therapy when indicated are clearly enormous, but the continued use of antibiotics
without any microbiological justification is dangerous and only leads to adverse events. The purpose of this review
is to highlight the inappropriate use of antibiotics in the NICUs, to exam the impact of antibiotic treatment in
preterm infants with negative cultures and to summarize existing knowledge regarding the appropriate choice of
antimicrobial agents and optimal duration of therapy in neonates with suspected or culture-proven sepsis in order
to prevent serious consequences.
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Sepsis represent the main cause of neonatal mortality ac-
counting for more than one million neonatal deaths
worldwide every year, and antibiotics are the most com-
monly prescribed medications in the neonatal intensive
care units (NICU) [1,2]. Sepsis has often nonspecific
signs and implies in serious consequences; as a result,
empirical antimicrobial therapy is promptly initiated in
symptomatic infants with suspected sepsis after obtain-
ing biological material for culture [1]. However, neonates
who do not have infection often receive antimicrobial
agents during hospital stay, and inappropriate empirical
antibiotic treatment may have serious side effects [3].
Nearly all extremely low birth weight infants (ELBW)
infants admitted to a NICU receive an empirical anti-
biotic treatment in the first postnatal days, in spite of
sterile cultures and low incidence of culture-proven bac-
terial sepsis in this population [1,3,4]. This observation
has been confirmed by a study of the National Institute* Correspondence: c.tzialla@smatteo.pv.it
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search Network on 6956 very low birth weight (VLBW)
infants, showing that 56% of all infants received at least
one course of antibiotic treatment, even if proven sepsis
was diagnosed in only 21% of all infants [5].
In this review we describe the use of antibiotics in the
NICU, focusing on the potential serious adverse effects
of inappropriate use; we identify the opportunities for
improving antibiotic prescription in the NICU, and we
discuss the future directions of antimicrobial therapy.Epidemiology of bacterial infections in the NICU
Neonatal sepsis can be classified as early-onset (EOS)
and late-onset (LOS) sepsis. EOS is most often caused
by group B streptococcus (GBS) (43%), followed by
Escherichia coli (15.5-29%). Among VLBW infants, the
rate of Escherichia coli infection exceeds that of GBS in-
fection (5.1 vs 2.1 per 1000 live births) [3].
LOS is mainly caused by Gram-positive bacteria (GPB)
(49%), most often coagulase-negative Staphylococcus
(CoNS) (45%). Gram-negative LOS is less common (23%),
but is associated with greater mortality in the NICU (19-
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ampicillin, gentamicin and cefotaxime commonly used
for empirical therapy appear to be appropriate. In a re-
cent study, investigators revealed that more than 94% of
the EOS isolates were susceptible to penicillin and gen-
tamicin, to amoxicillin and cefotaxime and to cefotaxime
alone. The LOS isolates (excluding CONS) had a more
than 96% susceptibility to flucloxacillin or amoxicillin
and gentamicin, to amoxicillin and cefotaxime, but only
78% to cefotaxime alone. The investigators concluded
that cefotaxime should not be included in the empiric
regimen of suspected sepsis, because of lower suscepti-
bility levels [7].
Blackburn et al., in a study of neonatal septicemia
found that only 1.4% of Gram-negative bacteria (GNB)
were resistant to penicillin plus gentamicin, whereas
10.4% of isolates tested against amoxicillin plus cefotax-
ime were resistant to this association [8].
Most hospital acquired CoNS are resistant to many
commonly prescribed antibiotics. In the NICU, entero-
cocci are less frequently isolated than staphylococcal
species. Nevertheless, ampicillin-resistant, and, more re-
cently, vancomycin-resistant enterococci have been de-
scribed and have become endemic in some NICUs [9].
GNB are often resistant to at least one class of antibiotics
usually used, and bacteria that are multi- or extensively-
resistant to conventional antibiotics are frequently isolated.
Pan-resistant pathogens are rarely isolated in the NICUs,
where resistance is most frequently found to piperacillin-
tazobactam, ceftazidime, and/or gentamicin [9,10].
Moreover, the emergence of extended-spectrum β-lac-
tamase (ESBL)-producing GNB confers resistance to
penicillins and cephalosporins, often coexisting with re-
sistance to other antibiotic categories as fluoroquino-
lones and aminoglycosides [9,11].Risks associated with empirical administration of
broad-spectrum antibiotics
The use of broad-spectrum antibiotics is associated with
different adverse effects: alteration of gut colonization,
emergency of resistant strains, and increasing risk of Can-
dida colonization and subsequent invasive candidiasis [4].
All antibiotics can alter gut colonization of the patient,
promoting either antibiotic resistance among normal
commensal organisms or the emergence of other patho-
gens [4,12].
A number of in vitro and in vivo studies have shown
that, although short courses of carbapanems and third-
generation cephalosporins cover a broad spectrum of
bacteria, their prolonged and intensive use selects resist-
ant bacteria. Overuse of third-generation cephalosporins
favors the emergence of ESBL-producing strains of GNB
in NICUs [10,13].In order to study the effects of empirical antibiotics on
the emergence of resistant pathogens, de Man et al. [14]
examined 436 infants admitted to 2 NICUs who were
assigned initially to either a narrow-spectrum antibiotic
regimen (penicillin or flucloxacillin plus tobramycin) or
a broad-spectrum regimen (amoxicillin plus cefotaxime)
and exchanged regimens after 6 months. The investiga-
tors demonstrated that the relative risk for colonization
with strains resistant to empirical therapy per 1000 pa-
tients at risk was 18-fold higher in the broad-spectrum
regimen group than in the narrow-spectrum regimen
group.
Exposure to broad spectrum antibiotics has been also
associated with the emergence of invasive candidiasis. In
a cohort of 3,702 ELBW infants, previous use of third
generation cephalosporins or carbapenems were associ-
ated with an increased risk of invasive candidiasis (OR
2.2, 95% CI 1.4-3.3). The incidence of candidiasis be-
tween centers varied from 2.4% to 20.2% and correlated
with the average number of days of broad spectrum anti-
biotic use per infant with sterile cultures throughout
hospitalization [15].
A multicenter cohort study of 128,914 neonates, re-
vealed that the use of ampicillin/cefotaxime during the
first 3 days after birth is associated with an increased
risk of death before discharge (OR 1.5, 95% CI 1.4-1.7)
compared with the use of ampicillin/gentamicin, even if
the authors highlighted that this observation may be
limited by selection bias. The authors concluded that,
for patients receiving ampicillin, the concurrent use of
cefotaxime during the first three days after birth is either
a surrogate for an unrecognized factor or is itself associ-
ated with an increased risk of death, compared with the
concurrent use of gentamicin [1].Adverse effects of prolonged courses of empirical
antibiotic treatment
For culture-proven sepsis a full course of antibiotics is
indicated. Conversely, concerns remain about the opti-
mal length of antibiotic therapy for clinical, not micro-
biologically demonstrated sepsis. Recent cohort studies
show an association between the duration of empirical
antibiotic therapy and mortality, necrotizing enterocolitis
(NEC) and LOS.
Cotten et al. [16] conducted a retrospective cohort ana-
lysis of 5,693 ELBW infants admitted to 19 tertiary cen-
ters. Of 5,693 infants, 4,039 survived >5 days, received
initial empirical antibiotic treatment and had sterile initial
blood culture at 72 hours of life. In a multivariate analysis
adjusted for risk factors, prolonged duration of therapy
was associated with increased odds of NEC or death or
death alone. Each additional day of antibiotic therapy was
associated with a 4% increase in the odds of NEC or death,
Table 1 Choice of antibiotics
EOS Penicillin + gentamicin
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crease in the odds of death alone.
A retrospective 2:1 control case analysis examined the
association between antibiotic exposure and the risk of
NEC. When neonates with sepsis were removed from
cohort, antibiotic duration increased the risk of NEC by
approximately 20% per day of exposure (OR = 1.2). Ex-
posure for >10 days resulted in nearly a threefold in-
crease in the risk of developing NEC [17].
Prolonged antibiotic therapy has also been associated
with LOS. A retrospective study of 365 infants ≤32 weeks
gestational age (GA) and ≤1500 g birth weight (BW),
who survived free of sepsis and NEC in the first week of
life, found that prolonged antibiotic therapy (≥5 days)
initiated on the day of birth was independently associ-
ated with LOS alone and the composite outcome of
LOS, NEC or death. Each additional day of antibiotics
was associated with a significantly increased risk of these
outcomes. For infants who received any initial empirical
antibiotic exposure, the adjusted attributable risk for
LOS, NEC or death was 32% and the number needed to
harm was 3 [18].- if Listeria monocytogenes: amoxicillin +
gentamicin
- if S.aureus: flucloxacillin + gentamicin
LOS First line: flucloxacillin + gentamicin
Second line:
- vancomycin + gentamicin (with caution)
- vancomycin + piperacillin/tazobactam
(to extend Gram-negative cover)
Third line: meropenem, ciprofloxacin





Currently: glycopeptide antibiotics are the
mainstay of therapy, especially vancomycin;
if necessary linezolid, clindamycin, rifampicin
and daptomycin could be alternative
regimens
In the future: novel cephalosporins like
ceftaroline and ceftobiprole; novel
lipoglycopeptide antibiotics are oritavacin
and dalbavancin; telavacin has been




cephalosporins are the antibiotics of choice;
carbapenems, colistin, co-trimoxazole,
ticarcillin-clavulanic acid could be the an
alternative; fluoroquinolone, ciprofloxacin,
tigecycline and tetraciclins could only be
justified in extreme cases.
In the future: treatment options are
extremely limited
Modified from: Russell AB, Sharland M, Heath PT. Improving antibiotic
prescribing in neonatal units: time to act. Arch Dis Fetal Neonatal 2012;
97:F141-146 and Gray JW, Patel M. Management of antibiotic-resistant
infection in the newborn. Arch Dis Child Educ Pract 2011 Aug;96(4):122–7.Recommendations for a judicious use of antibiotics
Choice of the antibiotic agent
Concerning the newborn infants, there are no random-
ized controlled trials that can definitely prove the best
choice of antibiotics. However, many authors agree that
an association of a penicillin or semisynthetic penicillin
(ampicillin) together with an aminoglycoside is effective
against microorganisms causing EOS, and therefore can
be considered the best empirical regimen [10,19,20].
For the treatment of suspected LOS, different authors
agree that the best regimen is an antistaphylococcal peni-
cillin (oxacillin, flucloxacillin) together with an aminog-
lycoside; the choice of vancomycin should be restricted
to microbiologically demonstrated cases of methicillin-
resistant Staphylococcus aureus (MRSA) or CoNS [19,20].
In a recent review, Sivanandan et al. [21] recom-
mended the same antibiotic combinations for empirical
therapy of EOS and LOS in neonates. In case of LOS in
an instable neonate and in areas where MRSA is preva-
lent, vancomycin and a third-generation cephalosporin
should be considered. For the treatment of suspected
early-onset meningitis the authors recommended a com-
bination of ampicillin and aminoglycoside or ampicillin
and cefotaxime, and in case of late-onset meningitis a
combination of an antistaphilococcal antibiotic (nafcillin
or vancomycin) plus a third-generation cephalosporin
with or without aminoglycoside.
Russel et al. [12] for the therapy of meningitis suggest
as first line treatment the combination of cefotaxime
and amoxicillin with or without gentamicin.Different authors state that empirical therapy should
never be started with a broad spectrum antibiotic such as a
third-generation cephalosporin or a carbapenem, and their
use should be restricted to particular cases [13,19]. Gray
et al. [10] suggest the use of piperacillin-tazobactam in the
units where aminoglycoside-resistant GBN are prevalent as
an alternative to third generation cephalosporins.
Russel et al. in a recent review, based on epidemiological
data from UK neonatal infection surveillance studies, sug-
gest for EOS and LOS treatment, antibiotic strategies re-
ported in Table 1 [12].
Duration of the antibiotic course
Culture-proven neonatal sepsis is treated with full course
of appropriate antibiotics; the appropriate duration of the
antibiotic course is more difficult to be established in case
of suspected (clinical) sepsis with negative cultures. Usu-
ally, antibiotics are discontinued as soon as blood cultures
are confirmed negative (48–72 hours), and if laboratory
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clude an infection [15,21-24].
In case of abnormal laboratory tests [white blood cell
count and C-reactive protein (CRP) at age 6–12 h] in
well-appearing neonate with negative blood culture Polin
and the Committee on Fetus and Newborn [11] (COFN)
suggest to continue empiric antibiotic therapy if mother
received antibiotics during labor and delivery in case of
infants <37 weeks’ gestation with risk factors for sepsis
and infants ≥ 37 weeks’ gestation born from mothers
with chorioamnionitis.
The algorithms for duration of empiric therapy when
cultures are sterile suggested by COFN generated discus-
sion about the lack of strong supportive evidence to guide
decisions to stop antimicrobials at 48 h in certain cases.
Cotten et al. [25] in a recent review highlight that
current studies are inadequate to specify appropriate
testing a timing of diagnostic tests in all situations in
which empirical therapy have been started. The authors
offer the following suggestions for the management of
term and late preterm neonates on empirical therapy for
EOS with negative cultures at 48 postnatal hours: i) con-
tinuation of treatment for 7 days if clinical signs of sep-
sis persist over 24 hours; ii) stop antibiotics at 48 hours
in asymptomatic neonates with initial (4 postnatal hours)
normal complete blood count (initial laboratory tests
drawn by risk factors), and in neonates with transient
clinical signs (lasting less than 24 h), and abnormal ini-
tial complete blood count, if serial CRP measurements
at 24 and 48 hours are low in a well-appearing neonate.
In case of culture-proven sepsis, Sivanandan et al. [21]
suggest that it is reasonable to treat for 10–14 days
with appropriate antimicrobial agents infants with blood
culture-proven sepsis without meningitis. However, in se-
lected situations [i.e. neonates >32 weeks GA and >1500 g
BW, who became asymptomatic with 5 days of appropriate
therapy], it is reasonable to discontinue antibiotics at 7–10
days if laboratory results are normal and cultures are sterile
in a well-appearing child. For neonatal meningitis, the
same authors suggest a duration of therapy of 14 to 21 days
for GBS, ≥ 21 days for Lysteria monocytogenes, a minimum
of 21 days for Gram-negative meningitis and 4 to 6 weeks
in cases complicated with intracranial abscesses.
Therapies for resistant pathogens
Even though an increase in vancomycin MIC values,
within the susceptible range, has been registered among
isolates of MRSA, CoNS or S. aureus strains vancomycin-
intermediate or vancomycin-resistant have not been iso-
lated from a NICU population so far. Consequently, glyco-
peptides remain an appropriate treatment for most
staphylococcal infections in this setting [9,26]. However in
case of unresponsive Gram-positive infections, linezolid
has been the most used in neonatology, even if the use ofdaptomycin have been described in few reports in case of
persistent staphylococcal bacteremia in neonates [26].
Several novel antibiotics active against GPB are currently
in diverse phases of development and clinical trials are on-
going. In particular, advanced-generation cephalosporins like
ceftaroline and ceftobiprole with activity against multidrug-
resistant staphylococci have been reported in adults
[26,27], as well as lipoglycopeptides agents with activity
against multidrug-resistant gram-positive pathogens like
oritavancin and dalbavancin and telavancin. All three
agents are promising alternatives for the treatment of
complicated skin and soft-tissue infections in adults but
there are no data about their pharmacokinetics in neo-
nates [26,28].
For serious antibiotic-resistant GNB infections, carba-
penems have become the mainstay of treatment with mer-
openem being the most widely used and doripenem as a
newer carbapenem with greater activity against Pseudo-
monas aeruginosa [10]. However rapid emergence of re-
sistance to these antibiotics means that the use of agents
such as colistin, fosfomycin and tigecycline must be con-
sidered. Colistin is largely experienced in the neonatal
population, but it must be kept in mind that is not effect-
ive against Proteus and Serratia. There is little experience
of using fosfomycin in neonates but is worth considering
as a final-resort therapy for extensively drug-resistant
GNB [10,26]. Tigecycline, active against hard to treat
pathogens like many multidrug-resistant GPB e GNB, is
inactive against Pseudomonas Aeruginosa [10,29], but due
to the possible effects on the bone growth in children, the




Antimicrobial stewardship programs (ASP) were intro-
duced in the 1980s, with the aim to reduce unnecessary
therapies. Nevertheless, only in 2007, the Infectious
Diseases Society of America, together with other profes-
sional organizations, published guidelines in order to im-
plement multidisciplinary ASP [30]. However, in spite of
positive experiences on adults, data about the conse-
quences of ASPs in neonatal settings are lacking.
Recently, several authors suggested different strategies
that might be helpful in a NICU that include implementa-
tion of systems for surveillance of bloodstream infections,
education of practitioners concerning the development of
resistance, use of narrow spectrum empirical antibiotic
policy and stop of empirical treatment or documented jus-
tification for continuation when blood cultures are nega-
tive, use of narrowest spectrum antibiotics for a proven
infection, formulary restriction and pre-authorization re-
quirements for selected antimicrobial agents like cephalo-
sporins, meropenem, vancomycin and teicoplanin [11,12].
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lines for neonates are often lacking, antibiotic steward-
ship principles like those proposed by the Get Smart for
Health Care Campaign of the Centers for Disease Con-
trol and Prevention can be applied to the NICU along
with the development of an interdisciplinary antimicro-
bial stewardship team and metrics to measure successful
implementation of ASP.
Development of innovative treatments
Spellberg et al. [32].suggest future strategies to combat
antibiotic-resistance like therapies with diminished poten-
tial to drive resistance (pe infusion of monoclonal anti-
bodies and white cells that kill microbes or biologic agents
that alter bacterial ability to trigger inflammation) and
treatments that alter host-microbe interactions like mod-
eration of host inflammation and limitation of microbial
growth (pe sequestration of host nutrients, probiotics ad-
ministration that compete with microbial growth).
Discovery of new antibiotics
The discovery of new antibiotics must face a number of
challenges that make the development of new antibiotic
drugs more difficult compared to other non-antibiotic
drugs. These have been well summarized in a recent re-
view by Lewis et al. [33].
First, the poor penetration of antibiotics in prokaryotic
cells requires the delivery of higher amounts of a com-
pound which, in turn, increases the risk of toxicity and
narrows the therapeutic range.
In addition, specifically targeting GNB is even more
challenging, as not only the inner membrane restricts the
penetration of hydrophilic substances, but also the outer
membrane further reduces the number of compounds that
may be effective, and the multidrug-resistant pumps ex-
trude any compounds that leak in through the outer
membrane.
Even when these pharmacodynamics-related issues are
resolved, the development of a new drug needs to face
the pharmacokinetics-related issues; indeed, the search
for molecules with physicochemical properties to im-
prove the likelihood of bioavailability (e.g. by applying
the Lipinski’s rules) may not match with the need of a
compound with physicochemical properties that im-
prove penetration into prokaryotes.
Once discovered, the compound must be tested in clin-
ical trials; however, the identification and recruitment of
patients infected with multi-resistant bacteria may be diffi-
cult, as most infections are caused by pathogens suscep-
tible to the available compounds.
Finally, there is modest return on investment on anti-
biotic development compared to other drugs. Indeed, anti-
biotic therapy is typically short-term, lasting only some
days, while therapies with cholesterol-lowering drugs orwith anti-hypertensive drugs last for years, or lifelong;
and, in any case, resistance to the new antibiotics will
eventually develop, limiting their use and the profits that
it produces.
Despite all these considerations, most of the potential
bacterial targets for antibiotics are still unexploited. It is
assumed that there are approximately 200 conserved es-
sential proteins in bacteria, but the current antibiotics
only hit few targets or pathways [33]. Future efforts
should focus on the discovery of compounds directed
against these new targets.
Conclusions
Sepsis represents the main cause of neonatal mortality
and antibiotics are the most commonly prescribed medi-
cations in the NICUs. Wise choice of antimicrobial agents
and optimal duration of therapy in neonates with suspected
or culture-proven sepsis is crucial in order to limit the use
of unnecessary broad spectrum antibiotic therapy, and to
provide local solutions to the world-wide race against anti-
microbial resistance. While there is an increasing choice of
drugs for treating multiresistant GPB, alternatives for GNB
will be seriously restricted for the foreseeable future. This
makes important the need to promote attitudes that fortify
measures for infection-control and to develop new treat-
ments that complement traditional approaches.
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